aTyr Pharma Inc

Financials

Flusso di cassa derivante dalle attività operative -15.3 M-33.08 M-41.89 M-33.22 M-69.12 M-61.99 M -61.99 M Flussi di cassa derivanti dalle attività di investimento 6.9 M-91.57 M47.24 M-20.13 M17.23 M-5.05 M -5.05 M Liquidità derivante dalle attività di finanziamento 16.14 M110.03 M5.45 M66.23 M39.86 M66.01 M 66.01 M Liquidità libera -15.5 M-33.27 M-43.53 M-37.44 M-69.18 M-62.06 M -62.06 M

aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.